Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 3;13(23):e036995.
doi: 10.1161/JAHA.124.036995. Epub 2024 Nov 22.

Improving Health Equity Through Standardization and Selective Expansion of Genetic Testing in Transthyretin Amyloidosis

Nishant R Shah  1 , Naveen Bellam  2
Affiliations
Editorial

Improving Health Equity Through Standardization and Selective Expansion of Genetic Testing in Transthyretin Amyloidosis

Nishant R Shah et al. J Am Heart Assoc. .
No abstract available

Keywords: Editorials, amyloidosis, hereditary, transthyretin‐related; genetic testing; health equity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Updated diagnostic algorithm in patients with suspected cardiac amyloidosis with transthyretin genetic testing in Black patients performed concurrently with laboratory testing to rule out light chain amyloidosis.
AL indicates light chain; HMDP, hydroxymethylene diphosphonate; PYP, pyrophosphate; SPECT, single‐photon emission computed tomography; Tc, technetium; and TTR, transthyretin.
See this image and copyright information in PMC

Comment on

References

    1. Bhatt K, Delgado DH, Khella S, Bumma N, Karam C, Keller A, Rosen AM, Bozas A, Shea A, Towne MC, et al. Hereditary transthyretin amyloidosis in patients referred to a genetic testing program. J Am Heart Assoc. 2024;13:e033770. doi: 10.1161/JAHA.123.033770 - DOI - PMC - PubMed
    1. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington‐Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–1016. doi: 10.1056/NEJMoa1805689 - DOI - PubMed
    1. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia‐Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, et al. Efficacy and safety of Acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132–142. doi: 10.1056/NEJMoa2305434 - DOI - PubMed
    1. Adams D, Tournev IL, Taylor MS, Coelho T, Plante‐Bordeneuve V, Berk JL, Gonzalez‐Duarte A, Gillmore JD, Low SC, Sekijima Y, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30:1–9. doi: 10.1080/13506129.2022.2091985 - DOI - PubMed
    1. Coelho T, Marques W Jr, Dasgupta NR, Chao CC, Parman Y, Franca MC Jr, Guo YC, Wixner J, Ro LS, Calandra CR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330:1448–1458. doi: 10.1001/jama.2023.18688 - DOI - PMC - PubMed

LinkOut - more resources